Résumé
Antiepileptic drugs (AEDs) can induce severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. We performed HLA genotyping and lymphocyte activation tests (LATs) for five AED-induced SCAR patients (three males and two females; aged 40–66 years old). Three patients were treated with carbamazepine (CBZ) for pain control, one was treated with phenytoin (PHT) for seizure prevention, and one was treated with valproic acid (VPA) for seizure prevention. One patient was diagnosed with CBZ-induced DRESS syndrome and the remaining patients were diagnosed with SJS. All patients recovered from SCARs after stopping suspicious drugs and supportive care. LATs were conducted to confirm the culprit drug responsible for inducing SCARs; and LAT results were positive for the suspected culprit drugs, in all except in one case. HLA-A,
Sujets)
Femelle , Humains , Mâle , Allèles , Anticonvulsivants , Carbamazépine , Cicatrice , Syndrome d'hypersensibilité médicamenteuse , Antigènes HLA-A , LATS , Activation des lymphocytes , Lymphocytes , Méthodes , Phénytoïne , Crises épileptiques , Syndrome de Stevens-Johnson , Acide valproïqueRésumé
Background@#Asians with Graves’ ophthalmopathy (GO) may have earlier compressive features due to narrower orbital apex and increased orbital volume. @*Objective@#To determine the risk factors associated with activity and severity of GO among adults. @*Methodology@#This was a cross-sectional analytical study of 163 adults with Graves’ disease (GD) from the outpatient clinics of the Philippine General Hospital. Demographics, clinical data, thyrotropin receptor antibody (TRAb) and urine iodine (UIE) levels were obtained. All participants were evaluated for activity and severity of GO by a single ophthalmologist. @*Results@#The population was predominantly composed of females (81%) and nonsmokers (69%), with a mean age of 35 + 11 years and median GD duration of 2 years. Median TRAb was 8.9 U/L while UIE was 171 mcg/L. Eight percent exhibited active GO, with 85% having mild disease. Multivariate analysis showed male sex to be associated with severe disease (OR 3.71, p=0.041), while elevated TRAb was associated with both active (OR 1.03, p=0.002) and severe GO (OR 1.02, p=0.007). @*Conclusion@#Lower rates of active and severe GO were seen compared to previous reports. In this population of predominantly nonsmokers, elevated TRAb emerged as a risk factor for active and severe GO.
Sujets)
Ophtalmopathie basedowienne , Maladie de Basedow , LATSRésumé
PURPOSE: The aims of this study were to evaluate the expression of the large tumor suppressor (LATS) genes LATS1 and LATS2 by immunohistochemical staining of gastric cancer, and to evaluate the clinicopathological significance of LATS expression and its correlation with overall survival (OS). MATERIALS AND METHODS: LATS1 and LATS2 expression in a tissue microarray was detected by immunohistochemistry, using 264 gastric cancer specimens surgically resected between July 2006 and December 2009. RESULTS: Low expression of LATS1 was significantly associated with more advanced American Joint Committee on Cancer (AJCC) stage (P=0.001) and T stage (P=0.032), lymph node (LN) metastasis (P=0.040), perineural invasion (P=0.042), poor histologic grade (P=0.007), and diffuse-type histology by the Lauren classification (P=0.033). Low expression of LATS2 was significantly correlated with older age (≥65, P=0.027), more advanced AJCC stage (P=0.001) and T stage (P=0.001), LN metastasis (P=0.004), perineural invasion (P=0.004), poor histologic grade (P<0.001), and diffuse-type histology by the Lauren classification (P<0.001). Kaplan-Meier survival analysis revealed significantly poor OS rates in the groups with low LATS1 (P=0.037) and LATS2 (P=0.037) expression. CONCLUSIONS: Expression of LATS1 or LATS2 is a significant marker for a good prognosis in patients with gastric cancer.
Sujets)
Humains , Classification , Gènes suppresseurs de tumeur , Immunohistochimie , Articulations , LATS , Noeuds lymphatiques , Métastase tumorale , Pronostic , Tumeurs de l'estomacRésumé
Polycystic ovarian syndrome [PCOS] accompanied with obesity and insulin resistance. Many findings have shown that fat tissue has an important role in creating and resisting of various disorders in PCOS. On the other hand, thyroid has an obvious and dominant role in metabolism [specially in the metabolism of lipids and carbohydrates]. Both PCOS and thyroid diseases are accompanied with disruption in function of hypothalamus - pituitary -gonad axis. This study aimed at finding the relationship between antithyroid antibodies and polycystic ovary syndrome. In this descriptive analytical study two groups of 54 women with the age ranges of 15 to 45 years from Shahrekord, Iran were selected and consecutively were entered the study. The first group [control group], did not have any thyroid disease, systemic disorders or PCOS based on the history, physical examinations and blood tests and they did not use any medicine. The second group [patients groups], did not have any thyroid diseases and systemic disorders based on the history, physical examinations and blood tests but they had PCOS. Antithyroid antibodies in both groups were measured and compared using K[2], t test and ANOVA. There was no significant difference in the prevalence and levels of antithyroid antibodies between PCOS group and control subjects [P>0.05]. The level of [T3] and [T4] was significantly higher in polycystic ovary syndrome than in control group [P<0.05]. It does not seem that to be more prevalent than in the healthy women and it is unlikely that they have an important role in pathophysiology of the disease
Sujets)
Humains , Femelle , Prévalence , Autoanticorps , Immunoglobulines thyréostimulantes , LATS , Maladies de la thyroïdeSujets)
Humains , Femelle , Adulte , LATS/physiologie , Mucinoses/classification , Mucines/physiologie , Myxoedème/physiopathologie , Récepteurs des hormones thyroïdiennes/physiologie , Glycosaminoglycanes , Acide hyaluronique , Hyperthyroïdie/complications , Dermatoses de la jambe/étiologie , Dermatoses de la jambe/anatomopathologie , Dermatoses de la jambe/physiopathologie , Mucines/composition chimique , Myxoedème/classification , Myxoedème/étiologie , Maladies de la thyroïde/complicationsRésumé
Pretibial myxedema is a condition in which there is loeal thickening of the skin by a mucin-like deposit; it is nearly always asosciated with ophthalmopathy and thyrotoxicosis, not infrequently becomes more pronounced after treatrnent of thyrotoxicosis. The precise cause of pretibial myxedema is not known, but it appears that IgG LATS represents an autoantibody against a thyroid antigen, retroorbital tiesue and tbe skin, so, pretibial myxedema is presumed to be the result of a local antigen-antibody tissue reaction. A 57-year-old man had the history of diabetes since 1964 and Graves disease since May 1980, he was treated with metimazole for 1 month, with improving thyrotoxicosis but developed the pretibial myxedema. The histologic findings showed considerable amount of mucin, especially hyaluronic acid with toluidin blue stain at PH 3.0. The lesions were improved by local application of 0.01 x fluocinolone acetonide ointment with occlusive dressing technique.